Pharmaceuticals

Traws Pharma

Traws Pharma's Oral COVID Drug Ratutrelvir Matches Paxlovid in Phase 2 Trial

Traws Pharma released FY2025 9 Months earnings on November 13 (EST), actual revenue USD 2.79 M, actual EPS USD 1.6358

Traws Pharma released FY2025 Q3 earnings on November 13 (EST), actual revenue USD 0 (forecast USD 60K), actual EPS USD -0.3441 (forecast USD -9.16)

Traws Pharma Extends Contracts with ChemDiv and Expert Systems to Support Ratutrelvir Clinical Development

Traws Pharma Initiates Phase 2 Clinical Trial for Ratutrelvir

Traws Pharma Initiates Phase II Clinical Trials for Ratutrelvir

Traws Pharma released FY2025 Q2 earnings on August 14 During-Market EST, actual revenue USD 2.733 M (forecast USD 60 K), actual EPS USD -0.1571 (forecast USD -8.75)

Traws Pharma released FY2025 Semi-Annual Earnings on August 14 During-Market (EST), Actual Revenue: USD 2.79 M, Actual EPS: USD 1.95

Traws Pharma to Release FY2025 Q2 Earnings on August 14 During-Market (EST), Forecast Revenue USD 60K, EPS USD -8.75

Traws Pharma Submits Briefing Document for TXM Accelerated Approval

Traws Pharma Announces Efficacy Data for Rigosertib in RDEB SCC Patients

Traws Pharma Discusses TXM Development Strategy

Traws Pharma released FY2025 Q1 earnings on May 15 (EST), actual revenue USD 57K (forecast USD 60K), actual EPS USD 2.0899 (forecast USD -8.04)

Traws Pharma Reports Strong Earnings and Submits FDA Briefing Document

Traws Pharma released FY2024 Q4 earnings on March 31 (EST), actual revenue 56 K USD (forecast 60 K USD), actual EPS 26.6048 USD (forecast -9.55 USD)

Traws Pharma released FY2024 annual earnings on March 31 (EST), actual revenue 226 K USD (forecast 230 K USD), actual EPS -35.2125 USD (forecast -154.35 USD)

Traws Pharma Shares Research Findings on ratutrelvir as a Potential Treatment for COVID-19

Traws Pharma Announces Positive Study Results for TXM in Treating H5N1 Avian Influenza

Traws Pharma Presents Positive Data on Avian Influenza Drug Candidate at 2025 ICAR Conference

Traws Pharma Reports Positive Results for Avian Influenza Antiviral Candidate TIVOXAVIR MARBOXIL

A SPAC III Acquisition

PicoCELA

Davis Commodities

Society Pass

ECD Automotive Design

Gauzy

Bristol-Myers Squibb Company

A SPAC III ACQUISITION CORP. COM NPV CL A (SUBS/RTS)02/01/2026

Paranovus ENT Tech

Cue BioPharma

禮來

羅氏(ADR)

ROCHE HOLDINGS AG

阿斯利康

諾華制藥

諾和諾德公司

中外制藥(ADR)

UCB(ADR)

第一三共株式會社(ADR)

大塚制藥(ADR)

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap